Tests prove first technology with anti Covid-19 action on our imported Architectural MDF panels. Eliminates 99.9% of the virus within 30 minutes
In the midst of the pandemic caused by Covid-19, all sectors of the economy and health entered a global race to create ways to combat and minimize the effects of the new virus. Our decorative panels were subjected to tests carried out by QuasarBio, in the level 3 biosafety laboratory (NB3) of the Institute of Biomedical Sciences of the University of São Paulo (ICB-USP), which proved the material's effectiveness in inactivating 99.9 % of the SARS-CoV-2 virus, responsible for the new Coronavirus, within 30 minutes.
The positive result is due to the use of Nanox Clean® technology, patented in the sector since 2015 with Nanox, a Brazilian startup that is a reference in the development of intelligent materials. Firstly designed to prevent the proliferation of fungi and bacteria in MDF, protection has been present in the entire decorative portfolio of the brand for five years, creating a lifetime coverage area for consumers who already own the product. With the scientific test, our panels consolidate as pioneers in the use of technologies that are proven to combat Covid-19 in the segment.
The Nanox technology creates a protective barrier based on nanotechnology that, when in contact with pathogens, inactivates viruses, fungi and bacteria. This is due to the natural property of its asset, silver, which is already known for its antibacterial action and, in the case of SARS-CoV-2, it is responsible for oxidizing the outer layer of the virus, eliminating it from the surface.
All our architectural panels receives Nanox Clean® protection through a melamine foil with silver micro-particles, which is pressed on the surface of MDF panels. The film is not affected by daily cleaning and is valid for life.
The tests were carried out using MDF samples with and without Nanox Clean® protection. The products were exposed to SARS-CoV-2 by immersing them in tubes that contained large amounts of the virus. Thus, the ability of the treated product to inactivate the viral particles in a contact interval of 10 minutes and 30 minutes was evaluated. In the minimum period, protection was already effective at 68.4%.
The trial took place at ICB-USP, the institute responsible for isolating SARS-Cov-2 in Brazil, and was led by Dr. Lúcio Freitas Júnior, professor and researcher at the University.